Sumant Kulkarni
Stock Analyst at Canaccord Genuity
(4.52)
# 1,063
Out of 5,088 analysts
427
Total ratings
45.3%
Success rate
9.4%
Average return
Main Sectors:
Stocks Rated by Sumant Kulkarni
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Reiterated: Buy | $21 → $32 | $16.49 | +94.06% | 10 | Oct 30, 2026 | |
| BIIB Biogen | Reiterated: Buy | $248 → $272 | $249.65 | +8.95% | 85 | Oct 29, 2026 | |
| LBRX LB Pharmaceuticals | Reiterated: Buy | $65 | $40.15 | +61.89% | 2 | Oct 28, 2026 | |
| VYGR Voyager Therapeutics | Reiterated: Buy | $12 | $1.76 | +581.82% | 42 | Oct 23, 2026 | |
| SPTX Seaport Therapeutics | Initiated Coverage: Buy | $28 | $21.10 | +32.70% | 1 | Oct 14, 2026 | |
| CRVO CervoMed | Reiterated: Buy | $18 | $1.75 | +928.57% | 23 | Oct 13, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $36 | $20.76 | +73.41% | 56 | Sep 25, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $64 → $78 | $37.96 | +105.48% | 21 | Sep 15, 2026 | |
| CMPS COMPASS Pathways | Reiterated: Buy | $20 | $12.19 | +64.07% | 27 | Sep 10, 2026 | |
| ANVS Annovis Bio | Reiterated: Buy | $17 | $1.02 | +1,566.67% | 12 | Aug 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $58 | $26.35 | +120.11% | 18 | Aug 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $10.36 | +93.05% | 20 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $39 | $21.50 | +81.40% | 18 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 → $210 | $146.38 | +43.46% | 42 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 → $24 | $7.72 | +210.88% | 3 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 | $3.90 | +1,182.05% | 12 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $120 → $36 | $0.863 | n/a | 10 | Jun 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $26.38 | n/a | 4 | Apr 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 → $53 | $19.20 | n/a | 8 | Nov 9, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $35 → $19 | $21.35 | n/a | 4 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $109 | $15.90 | n/a | 2 | Jun 14, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $193.70 | $12.41 | n/a | 7 | Dec 18, 2015 |
Biohaven
Oct 30, 2026
Reiterated: Buy
Price Target: $21 → $32
Current: $16.49
Upside: +94.06%
Biogen
Oct 29, 2026
Reiterated: Buy
Price Target: $248 → $272
Current: $249.65
Upside: +8.95%
LB Pharmaceuticals
Oct 28, 2026
Reiterated: Buy
Price Target: $65
Current: $40.15
Upside: +61.89%
Voyager Therapeutics
Oct 23, 2026
Reiterated: Buy
Price Target: $12
Current: $1.76
Upside: +581.82%
Seaport Therapeutics
Oct 14, 2026
Initiated Coverage: Buy
Price Target: $28
Current: $21.10
Upside: +32.70%
CervoMed
Oct 13, 2026
Reiterated: Buy
Price Target: $18
Current: $1.75
Upside: +928.57%
Acadia Pharmaceuticals
Sep 25, 2026
Reiterated: Buy
Price Target: $36
Current: $20.76
Upside: +73.41%
Definium Therapeutics
Sep 15, 2026
Reiterated: Buy
Price Target: $64 → $78
Current: $37.96
Upside: +105.48%
COMPASS Pathways
Sep 10, 2026
Reiterated: Buy
Price Target: $20
Current: $12.19
Upside: +64.07%
Annovis Bio
Aug 18, 2026
Reiterated: Buy
Price Target: $17
Current: $1.02
Upside: +1,566.67%
Aug 12, 2026
Reiterated: Buy
Price Target: $58
Current: $26.35
Upside: +120.11%
Aug 11, 2026
Reiterated: Buy
Price Target: $20
Current: $10.36
Upside: +93.05%
Aug 6, 2026
Reiterated: Buy
Price Target: $39
Current: $21.50
Upside: +81.40%
Aug 3, 2026
Reiterated: Buy
Price Target: $200 → $210
Current: $146.38
Upside: +43.46%
Jul 27, 2026
Reiterated: Buy
Price Target: $35 → $24
Current: $7.72
Upside: +210.88%
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $3.90
Upside: +1,182.05%
Jun 12, 2024
Downgraded: Hold
Price Target: $120 → $36
Current: $0.863
Upside: n/a
Apr 9, 2018
Reiterated: Hold
Price Target: n/a
Current: $26.38
Upside: n/a
Nov 9, 2016
Reiterated: Buy
Price Target: $66 → $53
Current: $19.20
Upside: n/a
Nov 7, 2016
Reiterated: Sell
Price Target: $35 → $19
Current: $21.35
Upside: n/a
Jun 14, 2016
Reiterated: Sell
Price Target: $109
Current: $15.90
Upside: n/a
Dec 18, 2015
Reiterated: Buy
Price Target: $193.70
Current: $12.41
Upside: n/a